<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.4 20241031//EN"
        "https://jats.nlm.nih.gov/publishing/1.4/JATS-journalpublishing1-4.dtd">
<article  article-type="research-article"        dtd-version="1.4">
            <front>

                <journal-meta>
                                                                <journal-id>van sağ bil derg</journal-id>
            <journal-title-group>
                                                                                    <journal-title>Van Sağlık Bilimleri Dergisi</journal-title>
            </journal-title-group>
                            <issn pub-type="ppub">2667-5072</issn>
                                        <issn pub-type="epub">2667-5072</issn>
                                                                                            <publisher>
                    <publisher-name>Van Yüzüncü Yıl Üniversitesi</publisher-name>
                </publisher>
                    </journal-meta>
                <article-meta>
                                        <article-id/>
                                                                <article-categories>
                                            <subj-group  xml:lang="en">
                                                            <subject>Clinical Sciences</subject>
                                                    </subj-group>
                                            <subj-group  xml:lang="tr">
                                                            <subject>Klinik Tıp Bilimleri</subject>
                                                    </subj-group>
                                    </article-categories>
                                                                                                                                                        <title-group>
                                                                                                                        <article-title>GLİOBLASTOMA’da 5-FU ve CELASTROL’ün SİTOTOKSİK ETKİSİ</article-title>
                                                                                                                                                                                                <trans-title-group xml:lang="en">
                                    <trans-title>THE CYTOTOXIC EFFECT of 5-FU AND CELASTRO L on GLIOBLASTO MA</trans-title>
                                </trans-title-group>
                                                                                                    </title-group>
            
                                                    <contrib-group content-type="authors">
                                                                        <contrib contrib-type="author">
                                                                <name>
                                    <surname>Taşpınar</surname>
                                    <given-names>Mehmet</given-names>
                                </name>
                                                                    <aff>VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, TIP FAKÜLTESİ, TEMEL TIP BİLİMLERİ BÖLÜMÜ, TIBBİ BİYOLOJİ ANABİLİM DALI</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Denizler</surname>
                                    <given-names>Farika Nur</given-names>
                                </name>
                                                                    <aff>VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, TIP FAKÜLTESİ, TEMEL TIP BİLİMLERİ BÖLÜMÜ, TIBBİ BİYOLOJİ ANABİLİM DALI</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Güven</surname>
                                    <given-names>Mustafa</given-names>
                                </name>
                                                                    <aff>VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, TIP FAKÜLTESİ</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Yüksek</surname>
                                    <given-names>Veysel</given-names>
                                </name>
                                                                    <aff>VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, ÖZALP MESLEK YÜKSEKOKULU</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Çetin</surname>
                                    <given-names>Sedat</given-names>
                                </name>
                                                                    <aff>VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ, TEMEL BİLİMLER BÖLÜMÜ, VETERİNERLİK BİYOKİMYASI ANABİLİM DALI</aff>
                                                            </contrib>
                                                    <contrib contrib-type="author">
                                                                <name>
                                    <surname>Dede</surname>
                                    <given-names>Semiha</given-names>
                                </name>
                                                                    <aff>VAN YÜZÜNCÜ YIL ÜNİVERSİTESİ, VETERİNER FAKÜLTESİ, TEMEL BİLİMLER BÖLÜMÜ, VETERİNERLİK BİYOKİMYASI ANABİLİM DALI</aff>
                                                            </contrib>
                                                                                </contrib-group>
                        
                                        <pub-date pub-type="pub" iso-8601-date="20190708">
                    <day>07</day>
                    <month>08</month>
                    <year>2019</year>
                </pub-date>
                                        <volume>11</volume>
                                        <issue>1</issue>
                                        <fpage>6</fpage>
                                        <lpage>10</lpage>
                        
                        <history>
                                    <date date-type="received" iso-8601-date="20181110">
                        <day>11</day>
                        <month>10</month>
                        <year>2018</year>
                    </date>
                                                    <date date-type="accepted" iso-8601-date="20181212">
                        <day>12</day>
                        <month>12</month>
                        <year>2018</year>
                    </date>
                            </history>
                                        <permissions>
                    <copyright-statement>Copyright © 2018, Van Sağlık Bilimleri Dergisi</copyright-statement>
                    <copyright-year>2018</copyright-year>
                    <copyright-holder>Van Sağlık Bilimleri Dergisi</copyright-holder>
                </permissions>
            
                                                                                                <abstract><p>Glioblastoma (GB), enmalign ve en agresif beyin tümörüdür.Fenotipik ve genotipik açıdan yüksek heterojeniteye sahip Glioblastomanın kesin bir tedavi şekli bulunmamaktadır. Glioblastomadakemoterapi uygulamaları tedavide önemlibir yer tutmaktadır. Ancak kemoterapötik direnç tedavi başarısını düşürmektedir. Kemoterapötik direnci azaltmak ve etkili birkemoterapi iç in bitkiselköken li antikanserojenik mo le küllereliştirilmeye çalışılmaktadır. Son yıllarda, önemlibir tedavi yaklaşımı olara k, bu mo leküllerin tek uygulanmalarının yanında kemoterapötik ajanlarla kombine uygulamaları artmaktadır. Bu çalış mada,kemoterapötik ajan 5-Fluorourac il ile doğal birbileşik olan Ce lastrol kombinasyonunun Glioblastomadaki sitotoksik etkisinin araştırılması amaç lan mıştır.MTT sitotoksisite testi sonucunda 2 µM Celastrolün, 50 µM 5-Fluorouracilin sitotoksik etkisini % 19 oranında arttırdığı, 0,5 ve 2 µM’lık Celastrolün100 µM’lık 5-Fluorouracilin sitotoksik etkisini sırasıyla% 25 ve %37 oranında arttırdığı saptanmıştır. Bu çalış ma, tüm kansertiplerinde 5-Fluorouracilin ile Celastrolün kombine etkisinin gösterildiğ i ilkçalış madır. Celastrolün 5-Fluorouracil ile birlikte kullanımının önemini ilkkez gösteren bu çalışma, yeni bir tedavi protokülünün geliştirilmesi amacıyladaha ileri düzey araştırmalara temel bir dayanak oluşturabilir.</p></abstract>
                                                                                                                                    <trans-abstract xml:lang="en">
                            <p>Glioblastoma is the mostmalign and agressive brain tumor. Glioblastomahas heterogeneityin terms of genotypicallyand phenotypically and alsothere is no precise treatment model. Chemotherapy has a bigrole in the treatment of glioblastoma but chemotherapeutic resistancedecrease the effectiveness of treatment.Anticancerogenic molecules whichderived from plants are devoloping withthe purpose of decreasing chemotheraupatic resistance and effective treatment. In recent years, as animportant treatment approach, the combination of these molecules withchemotherapeutic agents as well as single administration increases. In this study, it was aimed to investigate the cytotoxic effect of the combination of chemotherapeuticagent 5- Fluorouracil and a natural compound Celastrol in glioblastoma.As a result of the MTT cytotoxicity test, it wasdetermined that Celastrol (2µM) has increased the cytotoxic effect of 5- Fluorouracil(50 µM) by 19%, the cytotoxic effect of 5-Fluorouracil (100 µM) has increasedby celastrol (0.5 and 2 µM) inratio of 25% and 37% , respectively.This is the first studyto show the effects of 5-Fluorouracil and celastrol combinationin alltypes of cancer. This study, whichdemonstrated the importance of the use ofcelastrol with 5-Fluorouracil fo r the first time, may provide a basis for further research in order to develop a new treatment protocol</p></trans-abstract>
                                                            
            
                                                            <kwd-group>
                                                    <kwd>5-Florourasil</kwd>
                                                    <kwd>  Celastrol</kwd>
                                                    <kwd>  Glioblastoma</kwd>
                                                    <kwd>  Sitotoksisite</kwd>
                                            </kwd-group>
                                                        
                                                                            <kwd-group xml:lang="en">
                                                    <kwd>5-Fluorouracil</kwd>
                                                    <kwd>  Celastrol</kwd>
                                                    <kwd>  Glioblastoma</kwd>
                                                    <kwd>  Cytotoxicity</kwd>
                                            </kwd-group>
                                                                                                            </article-meta>
    </front>
    <back>
                            <ref-list>
                                    <ref id="ref1">
                        <label>1</label>
                        <mixed-citation publication-type="journal">Acra AM, Sakagami H , Mats uta T , Adachi K, Otsuki S, Nak ajima H ve ark. Effect of thr ee fluor ide compounds on the growth of oral normal and tumor cells. In Vivo.  2012; 26(4) :657-64.</mixed-citation>
                    </ref>
                                    <ref id="ref2">
                        <label>2</label>
                        <mixed-citation publication-type="journal">Blumenthal DT, Sc hulman SF. Survival outco mes in glioblastoma multiforme,including the impact of adj uvant chemot her apy. Expert Rev Neurother . 2005;5(5):683-90.</mixed-citation>
                    </ref>
                                    <ref id="ref3">
                        <label>3</label>
                        <mixed-citation publication-type="journal">Boridy S, Le PU, Petr ecca K, Maysinger D. Celastrol tar gets proteostasis and acts synergistically with a heat-shock protein 90 inhibitor to kill human glioblastoma cells. Cell Death Dis. 2014; 5:e1216.</mixed-citation>
                    </ref>
                                    <ref id="ref4">
                        <label>4</label>
                        <mixed-citation publication-type="journal">Chen M, Rose AE, Doudican N, Osman I, Orlow SJ. Cel astrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol Cancer Res. 2009;7(12):1946-53.</mixed-citation>
                    </ref>
                                    <ref id="ref5">
                        <label>5</label>
                        <mixed-citation publication-type="journal">Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter  B, Chen   CC,   ve   ark.   Phase   1    trial    of   vocimagene amir etrorepv ec and 5- fluorocytosine for r ecurrent high- grade glioma. Sci Transl Med. 2016;8(341):341ra75.</mixed-citation>
                    </ref>
                                    <ref id="ref6">
                        <label>6</label>
                        <mixed-citation publication-type="journal">Di Cesar e Mannelli L, Piccolo M, Maione F, Ferraro MG, Ir ace C, De Feo V, ve ark. Tanshinones from Salvia miltiorrhiza Bunge revert chemother apy-induc ed neuropathic pain and reduce glioblastoma cells malignancy. Biomed Pharmacother . 2018;105:1042-1049.</mixed-citation>
                    </ref>
                                    <ref id="ref7">
                        <label>7</label>
                        <mixed-citation publication-type="journal">Haar CP, Hebbar P, Wallace GC 4th, Das A, Vandergrift WA 3rd, Smith JA. ve ark. Drug resistance in glioblastoma: a mini review. Neurochem Res. 2012;37(6):1192-200.</mixed-citation>
                    </ref>
                                    <ref id="ref8">
                        <label>8</label>
                        <mixed-citation publication-type="journal">Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9.</mixed-citation>
                    </ref>
                                    <ref id="ref9">
                        <label>9</label>
                        <mixed-citation publication-type="journal">Hu Y, Wang S, Wu X, Zhang J, Chen R, Chen M. ve ark. Chinese herbal medicine der ived compounds for cancer therapy: a focus on hepat ocellul ar carcinoma. J Ethnopharmaco l. 2013; 149(3):601-12.</mixed-citation>
                    </ref>
                                    <ref id="ref10">
                        <label>10</label>
                        <mixed-citation publication-type="journal">Kang CW, Park MS, Kim NH, Lee JH , Oh CW, Kim HR, ve ark. Hexane extract from Sar gassum serrat ifo lium inhibits the cell proliferat ion and metast atic ability of human glioblastoma U87MG cells. Oncol Rep. 2015; 34(5): 2602-8.</mixed-citation>
                    </ref>
                                    <ref id="ref11">
                        <label>11</label>
                        <mixed-citation publication-type="journal">Kim SH, Kang JG , Kim CS, Ihm SH, Choi MG, Yoo HJ, v e ark. Cytotoxic effect of celastrol alone or in combination with paclitaxel on anapl astic thyroid carcinoma cells. Tumour Biol. 2017; 39(5):1010428317698369.</mixed-citation>
                    </ref>
                                    <ref id="ref12">
                        <label>12</label>
                        <mixed-citation publication-type="journal">Krex D, Klınk B, Hartmann C, Von Deımlıng A, Pıetsch T, ve ark. Long-term survival with glioblastoma multiforme. Brain: A J Neurol. 2007;130:2596-606.</mixed-citation>
                    </ref>
                                    <ref id="ref13">
                        <label>13</label>
                        <mixed-citation publication-type="journal">Li N, Xu M, Bao N, Shi W, Li Q, Zhang X. v e ark. Discovery of novel NO-r eleasing celastrol derivatives with Hsp90 inhibitio n and cytotoxic act ivities. Eur J Med  Chem. 2018; 160:1-8.</mixed-citation>
                    </ref>
                                    <ref id="ref14">
                        <label>14</label>
                        <mixed-citation publication-type="journal">Menei P, Jadaud E, Faisant N, Boisdron-Celle M, Michalak S, Fournier D, v e ark. Ster eotaxic implantation  of  5- fluorour acil-rel easing micros pher es in mal ignant gl ioma. Cancer. 2004;100(2):405-10.</mixed-citation>
                    </ref>
                                    <ref id="ref15">
                        <label>15</label>
                        <mixed-citation publication-type="journal">Messaoudi K, Clavreul A, Lagarce F. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide. Drug Discov Today. 2015;20(7):899-905.</mixed-citation>
                    </ref>
                                    <ref id="ref16">
                        <label>16</label>
                        <mixed-citation publication-type="journal">Miller CR, Williams CR, Buchsbaum DJ,  Gillespie  GY. Intratumor al 5- fl uorourac il produc ed by cytosine deaminas e/5-fluorocytosine gene ther apy is effective for experimental   human   glioblasto mas.  Canc er   R es. 2002; 62(3):773- 80.</mixed-citation>
                    </ref>
                                    <ref id="ref17">
                        <label>17</label>
                        <mixed-citation publication-type="journal">Nutthasirikul N, Hahnvajanawong C, Techasen A, Limpaiboon T, Leelayuwat C,Chau-In S. ve ark. Tar geting the ∆133p53 isoform can restor e chemosens itivity in 5-fluorour acil- resistant   cholangiocarcinoma  cells.   Int   J    Oncol. 2015; 47(6):2153-64.</mixed-citation>
                    </ref>
                                    <ref id="ref18">
                        <label>18</label>
                        <mixed-citation publication-type="journal">Paolillo M, Boselli C, Schinelli S. Glioblastoma under Siege: An Overview of Curr ent Therapeutic Str ategies . Brain Sci. 2018; 8(1).</mixed-citation>
                    </ref>
                                    <ref id="ref19">
                        <label>19</label>
                        <mixed-citation publication-type="journal">Sander P, Mostafa H, Soboh A, Schneider JM, Pala A, Baron AK ve ark. Vacquinol-1 inducible cell death in glioblastoma multiforme is counter regulated by TRPM7 activity induced by exogenous ATP. Oncotarget. 2017; (21):35124-35137.</mixed-citation>
                    </ref>
                                    <ref id="ref20">
                        <label>20</label>
                        <mixed-citation publication-type="journal">Sat hornsumetee S, Rich JN. Designer therapies for glioblastoma    multiforme.   Ann   N   Y    Acad    Sci. 2008; 1142:108-32.</mixed-citation>
                    </ref>
                                    <ref id="ref21">
                        <label>21</label>
                        <mixed-citation publication-type="journal">Tolba MF, Abdel-Rahman SZ. Pterostilbine, an act ive component of blueberries,sensitizes colon cancer cells to 5-fluorouracil cytotoxicity. Sci Rep. 2015;5: 15239.</mixed-citation>
                    </ref>
                                    <ref id="ref22">
                        <label>22</label>
                        <mixed-citation publication-type="journal">Touat M, Idbaih A, Sanson M, Ligon KL. Glioblastoma targeted therapy: updated approaches from recent biological insights. Ann Oncol. 2017;28(7):1457-1472.</mixed-citation>
                    </ref>
                                    <ref id="ref23">
                        <label>23</label>
                        <mixed-citation publication-type="journal">Uchibor i K, Kasamatsu A, Sunaga M, Yokota S, Sakur ada T, Kobayas hi E. ve ark. Est abl ishment and char acter izat ion of two 5-fl uorouracil-r esist ant hepatoc ellular carcinoma cell l ines. Int J Oncol. 2012; 40(4): 1005-10.</mixed-citation>
                    </ref>
                                    <ref id="ref24">
                        <label>24</label>
                        <mixed-citation publication-type="journal">Wang F, Zheng  Z,  Guan  J, Qi D, Zhou  S,  Shen  X  v e  ark. Ident ificat ion of a panel of genes as a prognostic biomarker for glioblastoma. EBioMedicine.  2018;37:68- 77.</mixed-citation>
                    </ref>
                                    <ref id="ref25">
                        <label>25</label>
                        <mixed-citation publication-type="journal">Wang Z, Zhai Z, Du X. Celastrol inhibits migr ation and invas ion through blocking the NF-κB pathway in ovarian cancer cells . Exp Ther Med. 2017;14(1):819-824.</mixed-citation>
                    </ref>
                                    <ref id="ref26">
                        <label>26</label>
                        <mixed-citation publication-type="journal">Zheng L, Fu Y, Zhuang L, Gai R, Ma J, Lou J. et . al. Simult aneous NF-κB inhibit ion and E-cadherin upregulation mediate mutually synergistic anticancer activity of celastrol and SAHA in vitro and in vivo. Int J Cancer. 2014;135(7):1721- 32.</mixed-citation>
                    </ref>
                                    <ref id="ref27">
                        <label>27</label>
                        <mixed-citation publication-type="journal">Zhu H, Yang W, He LJ, Ding WJ, Zheng L, Liao SD. et al. Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in comb ination wit h ABT- 737 in human hepatocellular carcinoma cells. PLo S One. 2012; 7(12):e52333.</mixed-citation>
                    </ref>
                            </ref-list>
                    </back>
    </article>
